Specifically, a meta-analysis of the ELIXA, LEADER, SUSTAIN-6, EXSCEL, REWIND and AMPLITUDE-O trials in type 2 diabetes estimated a 21% reduction in the risk of new-onset macroalbuminuria, eGFR decline, progression to ESKD or death attributable to kidney causes with GLP1-RAs compared with placebo [48]
Transdermal delivery works well for small, lipophilic (fat-soluble) molecules with specific molecular weights that can penetrate skin effectively
GLP-1 medications improve glucose control and reduce systemic inflammation, which may reduce glycation stress on collagen
Monitoring how your body reacts to different foods and maintaining regular check-ins with your provider is crucial
Watch the video to learn more about this amazingly affordable option
Forman HJ, Zhang H, Rinna A (2009) Glutathione: overview of its protective roles, measurement, and biosynthesis